Ocugen Inc

Затворен

1.24 -0.8

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.23

Максимум

1.25

Ключови измерители

By Trading Economics

Приходи

-1.5M

-19M

Продажби

1.7M

1.5M

EPS

-0.06

Марж на печалбата

-1,250.946

Служители

116

EBITDA

-987K

-17M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+686.18% upside

Дивиденти

By Acuity

Следващи печалби

6.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-200M

427M

Предишно отваряне

2.04

Предишно затваряне

1.24

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.07.2026 г., 23:56 ч. UTC

In after-market trading, Invesco Ltd shares are lower, moving from a high of 0.51% to a low of -0.81%. No specific news was identified.

31.07.2026 г., 23:56 ч. UTC

Social Media

Equifax Inc. shares are higher in after-market trading, buoyed by CEO Mark Begor's outlook on strong cash flow and $1.6 billion returned to shareholders.

31.07.2026 г., 23:56 ч. UTC

Dutch Bros Inc. shares are lower in after-market trading, fluctuating within a routine range since Friday's close. The price remains stable in its one-month trading range.

31.07.2026 г., 23:56 ч. UTC

MannKind Corp shares traded lower in after-market hours, retreating from earlier gains. The stock remains near the lower end of its one-month range.

31.07.2026 г., 23:56 ч. UTC

News

Citigroup maintained its Buy rating on Welltower and raised its price target to $275. Shares are modestly higher in after-market trading.

31.07.2026 г., 23:56 ч. UTC

iShares 1-3 Year Treasury Bond ETF trading roughly flat in after-market hours. Global equity indices are mixed, with U.S. markets lower and others higher.

31.07.2026 г., 23:56 ч. UTC

Indie Semiconductor Inc. shares are near unchanged in after-market trading, following a notable decline over the past month and remaining below the 20-day moving average.

31.07.2026 г., 23:56 ч. UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

31.07.2026 г., 23:56 ч. UTC

ETF Constituents

Vanguard Real Estate ETF trading was roughly flat after hours, with CSGP, VNO, and IIPR contributing negatively while ADC provided a modest positive impact.

31.07.2026 г., 23:56 ч. UTC

AeroVironment Inc shares are lower in after-market hours, with no specific news identified. The stock is near the lower end of its one-month range.

31.07.2026 г., 23:56 ч. UTC

Transocean Ltd shares are higher in after-market trading, continuing a trend of gains over the past three sessions. No specific news was identified for the move.

31.07.2026 г., 23:56 ч. UTC

Comcast shares are higher in after-market trading, showing volatility with no specific news to explain the movement. Broader market trends include gains in the Nikkei 225.

31.07.2026 г., 23:56 ч. UTC

Correlated Moves

Texas Instruments Inc. shows little change in after-market trading, reflecting broader weakness in the technology sector amid mixed Asian market performance.

31.07.2026 г., 23:56 ч. UTC

Barnes Group Inc. shares declined in after-market trading, showing minor fluctuations without specific news. Asian market results provided broader context for the movement.

31.07.2026 г., 23:56 ч. UTC

Diamondback Energy Inc shares are higher in after-market trading, continuing recent upward momentum and reflecting strong investor interest amid no specific news.

31.07.2026 г., 23:56 ч. UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

31.07.2026 г., 23:56 ч. UTC

Marathon Digital Holdings shares are higher in after-market trading, reflecting routine activity with no specific news identified. The stock remains below its 20-day moving average.

31.07.2026 г., 23:56 ч. UTC

MSCI Inc. shares advanced in after-market trading, supported by a rise in the Nikkei 225 Index and renewed interest in AI stocks.

31.07.2026 г., 23:56 ч. UTC

Block Inc shares are higher in after-market trading, buoyed by strong earnings from U.S. tech companies that eased concerns about AI infrastructure spending.

31.07.2026 г., 23:56 ч. UTC

Correlated Moves

Procter & Gamble Co shares declined in after-market trading, reflecting broader sector trends as Kimberly-Clark Corp also reported a drop.

31.07.2026 г., 23:56 ч. UTC

Adobe Inc shares are lower in after-market hours, with no specific news identified. The stock has declined since Friday's close, amid mixed broader market trends.

31.07.2026 г., 23:52 ч. UTC

Mexican Inflation Rate Set for Release Amid Mixed Market Sentiment and Global Price Pressures

31.07.2026 г., 23:52 ч. UTC

Mexico's Inflation Rate Release on August 7, 2026, Amidst Global Economic Pressures and Mixed Market Sentiment.

31.07.2026 г., 23:52 ч. UTC

South Korea's July Exports Expected to Grow 0.59% YoY Amid Cautious Optimism Following Record Highs

31.07.2026 г., 23:52 ч. UTC

Rising MBA 30-Year Mortgage Rates Reach Highest Levels Since Last Year, Signaling Caution Among Homebuyers Amid Economic Pressures.

31.07.2026 г., 23:51 ч. UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

31.07.2026 г., 23:51 ч. UTC

Social Media
Correlated Moves
News

Meta Platforms Inc shares are lower in after-market hours, pressured by broader market weakness and concerns over rising AI spending following a disappointing earnings report.

31.07.2026 г., 23:51 ч. UTC

Interactive Brokers Group Inc is lower in after-market trading, reflecting the broader market's significant decline and a position below its 20-day moving average.

31.07.2026 г., 23:51 ч. UTC

Solaredge Technologies Inc shares declined in after-hours trading, reflecting broader market trends. No specific company news was identified to explain the movement.

31.07.2026 г., 23:51 ч. UTC

Evolent Health Inc shares are higher in after-market hours, rebounding from nine consecutive daily declines despite remaining below their 20-day moving average.

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

686.18% нагоре

12-месечна прогноза

Среден 9.67 USD  686.18%

Висок 12 USD

Нисък 7 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

6

Купи

0

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat